The relevance of the individual genetic background for the toxicokinetics of two significant neurodevelopmental toxicants: Mercury and lead

被引:100
作者
Gundacker, Claudia [1 ]
Gencik, Martin [2 ]
Hengstschlaeger, Markus [1 ]
机构
[1] Med Univ Vienna, Inst Med Genet, A-1090 Vienna, Austria
[2] Praxis Humangenet, A-1090 Vienna, Austria
关键词
Toxicogenetics; Mercury; Lead; Genotype-phenotype association; Individual susceptibility; GLUTATHIONE-S-TRANSFERASE; AMINOLEVULINIC-ACID DEHYDRATASE; VITAMIN-D-RECEPTOR; SINGLE NUCLEOTIDE POLYMORPHISMS; METALLOTHIONEIN MESSENGER-RNA; SITE-DIRECTED MUTAGENESIS; BLOOD-BRAIN-BARRIER; NULL PREGNANT MICE; P-GLYCOPROTEIN; INORGANIC MERCURY;
D O I
10.1016/j.mrrev.2010.06.003
中图分类号
Q81 [生物工程学(生物技术)]; Q93 [微生物学];
学科分类号
071005 ; 0836 ; 090102 ; 100705 ;
摘要
The heavy metals mercury and lead are well-known and significant developmental neurotoxicants. This review summarizes the genetic factors that modify their toxicokinetics. Understanding toxicokinetics (uptake, biotransformation, distribution, and elimination processes) is a key precondition to understanding the individual health risks associated with exposure. We selected candidate susceptibility genes when evidence was available for (1) genes/proteins playing a significant role in mercury and lead toxicokinetics, (2) gene expression/protein activity being induced by these metals, and (3) mercury and lead toxicokinetics being affected by gene knockout/knockdown or (4) by functional gene polymorphisms. The genetic background is far better known for mercury than for lead toxicokinetics. Involved are genes encoding L-type amino acid transporters, organic anion transporters, glutathione (GSH)-related enzymes, metallothioneins, and transporters of the ABC family. Certain gene variants can influence mercury toxicokinetics, potentially explaining part of the variable susceptibility to mercury toxicity. Delta-aminolevulinic acid dehydratase (ALAD), vitamin D receptor (VDR) and hemochromatosis (HEE) gene variants are the only well-established susceptibility markers of lead toxicity in humans. Many gaps remain in our knowledge about the functional genomics of this issue. This calls for studies to detect functional gene polymorphisms related to mercury- and lead-associated disease phenotypes, to demonstrate the impact of functional polymorphisms and gene knockout/knockdown in relation to toxicity, to confirm the in vivo relevance of genetic variation, and to examine gene-gene interactions on the respective toxicokinetics. Another crucial aspect is knowledge on the maternal-fetal genetic background, which modulates fetal exposure to these neurotoxicants. To completely define the genetically susceptible risk groups, research is also needed on the genes/proteins involved in the toxicodynamics, i.e., in the mechanisms causing adverse effects in the brain. Studies relating the toxicogenetics to neurodevelopmental disorders are lacking (mercury) or very scarce (lead). Thus, the extent of variability in susceptibility to heavy metal-associated neurological outcomes is poorly characterized. (C) 2010 Elsevier B.V. All rights reserved.
引用
收藏
页码:130 / 140
页数:11
相关论文
共 150 条
[41]   Effects of lead on rat kidney and liver: GST expression and oxidative stress [J].
Daggett, DA ;
Oberley, TD ;
Nelson, SA ;
Wright, LS ;
Kornguth, SE ;
Siegel, FL .
TOXICOLOGY, 1998, 128 (03) :191-206
[42]   TRANSPORT OF PB-203 AT THE BLOOD-BRAIN-BARRIER DURING SHORT CEREBROVASCULAR PERFUSION WITH SALINE IN THE RAT [J].
DEANE, R ;
BRADBURY, MWB .
JOURNAL OF NEUROCHEMISTRY, 1990, 54 (03) :905-914
[43]   Pharmacokinetic role of L-type amino acid transporters LAT1 and LAT2 [J].
del Amo, Eva M. ;
Urtti, Atto ;
Yliperttula, Marjo .
EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES, 2008, 35 (03) :161-174
[44]   Cellular glutathione and thiols metabolism [J].
Dickinson, DA ;
Forman, HJ .
BIOCHEMICAL PHARMACOLOGY, 2002, 64 (5-6) :1019-1026
[46]   Genetic variation in glutathione-related genes and body burden of methylmercury [J].
Engstrom, Karin Schlawicke ;
Stromberg, Ulf ;
Lundh, Thomas ;
Johansson, Ingegerd ;
Vessby, Bengt ;
Hallmans, Goeran ;
Skerfving, Staffan ;
Broberg, Karin .
ENVIRONMENTAL HEALTH PERSPECTIVES, 2008, 116 (06) :734-739
[47]   The molecular pharmacology of organic anion transporters: from DNA to FDA? [J].
Eraly, SA ;
Bush, KT ;
Sampogna, RV ;
Bhatnagar, V ;
Nigam, SK .
MOLECULAR PHARMACOLOGY, 2004, 65 (03) :479-487
[48]   The human organic anion transporter 3 (OAT3; SLC22A8):: genetic variation and functional genomics [J].
Erdman, AR ;
Mangravite, LM ;
Urban, TJ ;
Lagpacan, LL ;
Castro, RA ;
de la Cruz, M ;
Chan, W ;
Huang, CC ;
Johns, SJ ;
Kawamoto, M ;
Stryke, D ;
Taylor, TR ;
Carlson, EJ ;
Ferrin, TE ;
Brett, CM ;
Burchard, EG ;
Giacomini, KM .
AMERICAN JOURNAL OF PHYSIOLOGY-RENAL PHYSIOLOGY, 2006, 290 (04) :F905-F912
[49]   Cellular glutathione peroxidase deficiency and endothelial dysfunction [J].
Forgione, MA ;
Weiss, N ;
Heydrick, S ;
Cap, A ;
Klings, ES ;
Bierl, C ;
Eberhardt, RT ;
Farber, HW ;
Loscalzo, J .
AMERICAN JOURNAL OF PHYSIOLOGY-HEART AND CIRCULATORY PHYSIOLOGY, 2002, 282 (04) :H1255-H1261
[50]   Cytoprotective responses in the Mediterranean mussel exposed to Hg2+ and CH3Hg+ [J].
Franzellitti, Silvia ;
Fabbri, Elena .
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 2006, 351 (03) :719-725